MaxCyte, Inc. (MXCT) vs Unicycive Therapeutics, Inc. (UNCY)

A side-by-side comparison of MaxCyte, Inc. and Unicycive Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — MXCT vs UNCY

growth of $100 · dividends reinvested · last 5y
MXCT -93.6% (-42.4%/yr)UNCY -84.8% (-31.4%/yr)UNCY compounded faster over this window
020406080100Start $10020222023202420252026$6$15
MXCT UNCY

MXCT vs UNCY: by the numbers

  • •MXCT is the larger company ($117M vs $112M market cap).
  • •Both run net losses; UNCY's is the smaller (0.00% vs -114.77% net margin).

Metrics side by side

Valuation

MetricMXCTUNCY
P/S ratio3.76N/A
P/B ratio0.742.11

Profitability

MetricMXCTUNCY
Gross margin79.43%0.00%
Operating margin-137.12%0.00%
Net margin-114.77%0.00%
ROE-22.45%-66.12%
ROIC-19.83%-62.15%

Growth (annualized)

MetricMXCTUNCY
Revenue CAGR (5Y)1.46%N/A
Total return CAGR (5Y)-37.32%-32.14%

Frequently asked

How have MXCT and UNCY total returns compared?
Over the past 5 years, MXCT delivered -37.32% and UNCY delivered -32.14% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.